万古霉素联合头孢唑林作为标准术前抗生素预防对器械脊柱融合术后手术部位感染的影响
该回顾性队列研究评估了2010年起实施的静脉万古霉素联合头孢唑林预防方案对器械脊柱融合术后因感染翻修手术的影响。结果显示,感染翻修率从2005-2009年的4%(n=57)降至2011-2015年的2%(n=44)(P<0.001),调整后感染翻修比值比降低50%(OR 0.50;95%CI 0.33, 0.76),任何原因翻修率也从14%降至9%(P<0.001),感染病原体无显著差异(P=0.22)。
要点
- 感染翻修率从4%(n=57)降至2%(n=44)(P<0.001)
- 调整后感染翻修比值比降低50%(OR 0.50;95%CI 0.33, 0.76)
- 任何原因翻修率从14%降至9%(P<0.001),病原体无显著差异(P=0.22)
核心结论
- 该自然实验显示万古霉素联合头孢唑林的术前预防方案对器械脊柱融合术后感染翻修手术有一定效用,包括感染翻修手术的显著减少。
- 作者认为这是其所知首次考虑采用静脉万古霉素联合头孢唑林作为预防药物的统一机构方案。
研究设计与样本
- 回顾性队列研究,采用前后对比分析评估抗生素预防方案改变对器械脊柱融合术后手术部位感染的影响。
- 收集2005年至2009年及2011年至2015年所有符合条件患者的数据。
- 使用逻辑回归技术评估预防性抗生素方案对所有翻修手术及感染相关翻修手术的未调整结果,随后依次调整社会人口学因素和手术特征。
- 证据等级为2。
主要发现
- 因感染诊断而进行的翻修手术率从2005-2009年的4%(n=57)降至2011-2015年的2%(n=44)(P<0.001)。
- 任何原因翻修手术发生率从2005-2009年的14%降至2011-2015年的9%(P<0.001)。
- 调整分析中,方案引入后感染翻修手术的比值比降低50%(OR 0.50;95%CI 0.33, 0.76)。
- 2005-2009年与2011-2015年间导致手术部位感染的病原体无显著差异(P=0.22)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY DESIGN: Retrospective cohort study. OBJECTIVE: To assess whether administration of prophylactic vancomycin, in addition to cefazolin decreased revision surgeries for postoperative infection (SSI) as well as the need for revisions overall. SUMMARY OF BACKGROUND DATA: In 2010 our institution implemented an antibiotic prophylaxis regimen consisting of intravenous vancomycin and cefazolin that applied to all patients receiving surgical implants. The impact of this change in prophylactic antibiotic regimen on SSIs following instrumented spinal fusions remains unknown. METHODS: We conducted a prepost analysis evaluating the effect of the change in antibiotic prophylaxis on SSIs following instrumented spinal fusions. We collected data on all eligible patients over the course of 2005 to 2009 and 2011 to 2015. We used logistic regression techniques to evaluate unadjusted results for the prophylactic antibiotic protocol on all revision surgeries, as well as those for SSI, followed by sequential adjustments for sociodemographic factors and surgical characteristics. RESULTS: Revision surgeries performed for a diagnosis of infection were reduced from a rate of 4% (n = 57) in the period 2005 to 2009 to 2% (n = 44) over 2011 to 2015 (P < 0.001). At the same time, the incidence of revision surgeries for any cause was also reduced (14% in 2005-2009 vs. 9% in 2011-2015; P < 0.001). In adjusted analysis, the odds of a revision procedure for SSI were reduced by 50% following introduction of the protocol (OR 0.50; 95% CI 0.33, 0.76). No significant difference in the organisms responsible for SSI was identified between 2005 and 2009 and 2011 and 2015 (P = 0.22). CONCLUSION: This natural experiment has shown some utility for a preoperative prophylactic antibiotic regimen of vancomycin and cefazolin, including meaningful reductions in revision procedures performed for SSI. This is the first effort we are aware of to consider a uniform institutional protocol that employs the use of intravenous vancomycin and cefazolin as prophylactic agents. LEVEL OF EVIDENCE: 2.
引用
- Lopez WY, Rider SM, Nwosu K, et al. The Impact of Vancomycin and Cefazolin as Standard Preoperative Antibiotic Prophylaxis on Surgical Site Infections Following Instrumented Spinal Fusion. Spine (Phila Pa 1976). 2019. PMID: 30830037. doi:10.1097/BRS.0000000000002839
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。